TRANSDERMAL IONTOPHORETIC DELIVERY OF ATENOLOL IN COMBINATION WITH PENETRATION ENHANCERS: OPTIMIZATION AND EVALUATION ON SOLUTION AND GELS
Abstract
In the present investigation, we prepared Atenolol (1.5 % w/w) solution and various polymer formulations by incorporating the tween-20 or L-menthol, as a penetration enhancers and its effect on permeation of the drug through the excised abdominal rat skin were used to examined by using the vertical Franz-type diffusion cell. The physicochemical interactions between Atenolol and various polymers were investigated by performing the assay, ultra violet absorption maxima, Fourier transform infrared spectroscopy and it was further confirmed by thin layer chromatography studies, from which drug did not show any evidence of interaction with the polymers. We found that, L-menthol was superior than tween-20 to iontophoresis [current density applied 0.5 mA/cm2 and 90:10 (on: off) ratio], in enhancing the transdermal permeation of Atenolol; it enhanced the flux of Atenolol by more than 2-folds, comparison to the preparations without penetration enhancer via passive diffusion, and 3 folds increased using iontophoresis alone with a shorter lag time. Atenolol also showed good stability in gel formulations. The basic parameters like % loading dose released at the end of the study, permeation coefficient and steady state flux (Jss) were calculated and showed statistically significant difference (p<0.05). The results indicated that suitable iontophoretic delivery with desired permeability could be appeared and the cumulative amount-time curves were suitable to fit by a zero order equations which indicated a steady state permeation rate or sustained effect could be achieved from hydrogel; when it is combined with penetration enhancer, L-menthol. The results demonstrate that the semisolid gel formulations are more applicable than solution as a transdermal iontophoretic delivery system to administer clinically. Electrically assisted transdermal delivery of Atenolol significantly increased transport compared to passive delivery. Also, rapid and modulated delivery was shown to be feasible by programming the electrical parameters.
Keywords:
transdermal delivery; iontophoresis; Atenolol; solution; gel formulations; penetration enhancers; Franz cell; rat skinDOI
https://doi.org/10.25004/IJPSDR.2009.010208References
2. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development? Curr. Drug. Dev. 2004; 1: 81-92.
3. Roberts MS, Lai PM, Cross SE, Yoshida NH. Solute Structure as a determinant of Iontophoretic transport. In: Potts RO, Guy RH (ed.) Mechanisms of Transdermal Drug Delivery. New York, 1997, p 291.
4. Préat V, Jadoul A, Regnier V, Vanbever R.Electrically enhanced transdermal drug delivery. Res. Themes. 1996; 11: 49-50.
5. Gattani SG, Gaud RS, Chaturvedi SC, Surana SJ, Nandve MD. Iontophoresis: “noninvasive” electronically controlled technology. The Pharma. Rev. 2005; 12: 113-118.
6. Cleary GW, Beskar E. Transdermal and transdermal like delivery system oppourtunities. Business Briefing: Pharmatech. 2004; 1-4.
7. Sam Saks MD. Beyond the patch: ALZA’s new frontier in drug delivery. Dev.Times. 2002; 1:1-11. Delivery
8. Denet AR, Ucakar B, Pre´at V. Transdermal delivery of Timolol and Atenolol using electroporation and iontophoresis in combination: A mechanistic approach. Pharm. Res. 2003; 20: 1946-1951.
9. Jacobsen J. Buccal iontophoretic delivery of atenolol. HCl employing a new in vitro three-chamber permeation cell. J. Control. Rel. 2001; 70: 83-95.
10. Fang JY, Huang YB, Lin HH, TsaiYH. Transdermal iontophoresis of sodium nonivamide acetate. IV. Effect of polymer formulations. Int. J. Pharm.1998; 173:127–140.
11. Nolan LMA, Corish J, Corrigan OI, Fitzpatrick D. Iontophoretic and chemical enhancement of drug delivery Part I: Across artificial membranes. Int. J. Pharm. 2003; 257: 41–55.
12. Kanikkannana N, Singh J, Ramarao P.In vitro transdermal iontophoretic transport of timolol maleate: effect of age and species. J. Control. Rel. 2001; 71: 99-105.
13. Bhaskaran S, Harsha NS.Effect of permeation enhancer and iontophoresis on permeation of atenolol from transdermal gels. Ind. J. Pharm. Res., 2000; 6: 424-426.
14. Attia MA, Gibaly IE, Shaltout SE, Fetih GN. Transbuccal permeation, anti- inflammatory activity and clinical efficacy of piroxicam formulated in different gels.Int. J. Pharm. 2004; 276: 11-28.
15. Stamatialis DF, Rolevink HHM, Koops GH. Controlled transport of timolol maleate through artificial membranes under passive and iontophoretic conditions. J. Control. Rel. 2002; 81: 335–345.
16. Caplar V, Mihun ZM, Hofman H, Kuftinee J, Kajfez F, Nagl A, Blazevic N. Atenolol Profile, In: Florey K (ed.) Analytical profiles of drugs substances New Yark, 1984, 13: p. 1-25.
17. Akimoto M, Kawahara M, Matsumoto M, Matsubayashi H. Development of the pulsed direct current iontophoresis and its clinical application. Progress in Electromagnetics Research Symposium. 2006; 3:157-162.
18. Geest RV, Elshove DAR, Danhof M, Lavnjsen APM, Bodde HE. Non- invasive assessment of skin barrier integrity and skin irritation following iontophoretic current application in humans. J. Control.Rel. 1996; 41: 205–213.
19. Fang JY, Sung KC, Lin HH, Fang CL. Transdermal iontophoretic delivery of diclofenac sodium from various polymer formulations: in vitro and in vivo studies. Int. J. Pharm. 1999; 178: 83-92.
20. Nandy BC, Gupta RN. Development of spectrophotometric analysis method of Atenolol gel formulations. THE PHARMA REVIEW 2007; 7: 146-150.
21. Salem H. Spectrophotometric determination of beta-adrenergic blocking agents in Pharmaceutical formulations. J. Pharm. Biomed. Anal. 2002; 29: 527-538.
22. Al-Ghannam SM, Belal F. Kinetic Spectrophotomtric determination of atenolol in dosage forms. J. AOAC Int. 2002; 85: 817-823.
23. Aqil M, Sultan Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: In vitro characterization. Acta Pharm. 2003; 53:119–125.
24. Fang JY, Huang YB, Wu PC, Tsai YH. Transdermal iontophoresis of sodium nonivamide acetate II: optimization and evaluation on solutions and gels. Int. J. Pharm. 1996; 145: 175-186.
25. Kikwai L, Babu RJ, Prado R, Kolot A, Armstrong CA, Ansel JC, Singh M. In vitro and in vivo evaluation of topical formulations of Spantide II. AAPS Pharm. Sci. Tech. 2005; 6: E565-572.
26. Khalili MA, Meidan VM, Michniak BB. Iontophoretic Transdermal Delivery of Buspirone Hydrochloride in Hairless Mouse. AAPS Pharm Sci Tech 2003; 5: 1-11.
Published
Abstract Display: 251 
PDF Downloads: 371 How to Cite
Issue
Section
Copyright (c) 2009 B. C. Nandy, R. N. Gupta, V. K. Rai, S. Das, L. K. Tyagi, S. Roy, K. C. Meena
This work is licensed under a Creative Commons Attribution 4.0 International License.
